Skip to main content

A multimodal approach to accelerate drug discovery and development in Alzheimer’s disease

Project description

Combining genetics and imaging for AD drug discovery

Clinical trials on new drugs against Alzheimer's disease (AD) have failed to show any efficacy in slowing disease progression, underscoring the importance of new therapeutic targets. Towards this goal, the EU-funded MAP-AD project will use autosomal and X chromosome genetic variants to identify novel molecular pathways and putative therapeutic targets. Scientists will decipher the impact of specific genetic variants on gene expression through the analysis of post-mortem brain tissue. Combined with multimodal brain imaging analysis, the genomics information will be applied to correctly enrol patients in clinical trials expediting the development of drugs for the prevention and treatment of AD.

Call for proposal

H2020-MSCA-IF-2019
See other projects for this call

Funding Scheme

MSCA-IF-GF - Global Fellowships

Coordinator

INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE
Address
Boulevard De L'hopital 47
75013 Paris
France
Activity type
Research Organisations
EU contribution
€ 257 619,84

Partners (1)

BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
United States
Address
Serra Mall 450
94305 2004 Stanford
Activity type
Higher or Secondary Education Establishments